This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
Explore Eliquis
NVAF
Explore ELIQUIS in non-valvular atrial fibrillation
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II).1
VTE-DVT / PE
Explore ELIQUIS in deep vein thrombosis / pulmonary embolism
ELIQUIS (apixaban) is indicated for prevention treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Prescribing Eliquis
Dosing and Switching
Patient Resource Materials
Additional Support
Useful Links
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
DVT = Deep Vein Thrombosis NVAF = Non-Valvular Atrial Fibrillation PE = Pulmonary Embolism
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
Date of Preparation: September 2025 | Job Description: 432-IE-2500024